Released: Wednesday, May 13, 2026, Source: Dongfang Caijing (Artery Network)

Artery Network learned that Shanghai ImmuNova Biotechnology Co., Ltd. ("ImmuNova") announced the completion of 250 million yuan in Series A financing. This round was led by Vivo Capital, with follow-on investment from Gaomai Yuanhang, and significant oversubscribed additional investment from existing shareholders Xicheng Jinrui and Taiyu Investment. The funds will primarily be used to accelerate the continued R&D of the gene-edited animal platform, the commercial implementation of the fully human antibody rabbit platform, the construction of the AI antibody drug screening platform, the development of framework antibodies for complex targets, and the company's daily operations and team expansion.

Founded in 2020, ImmuNova focuses on building the next-generation antibody discovery platform through gene editing technology. The company's independently developed MASIRT® (Massive-fragment Across Species In situ Replacement Technology) achieves three core breakthroughs: utilizing a linear artificial chromosome loading strategy to significantly increase gene fragment loading capacity; completing Mb-level DNA fragment in situ replacement in a single operation, substantially reducing editing rounds; and the MASIRT technology is not species-restricted, having achieved large-fragment replacement across multiple species. Beyond the fully human mouse platform, the company has further strategically positioned itself with the globally original ImmuAlpaca® Alpaca-Mouse platform, the fully human rabbit, and rabbit-derived single heavy chain antibody rabbit platform, filling market gaps in multi-species, high-diversity model animal fields, and has completed global patentcoverage (coverage) across major markets including Mainland China, Europe, the United States, and Japan. The synergy of these three technological advantages has dramatically compressed the construction cycle of fully human antibody animal platforms, significantly improving antibody screening efficiency and success rates, providing more efficient source innovation tools for antibody drug R&D. The company is simultaneously advancing the construction of the MabAI® AI antibody discovery platform, leveraging multi-species immune data yielding over 100 million high-quality sequences annually to build AI antibody generation and characterization models, greatly enhancing screening efficiency and drug-like properties, creating an innovation system with dual-wheel drive of "fully human model animals + AI empowerment."

ImmuNova has established a cooperation system covering multiple well-known pharmaceutical enterprises domestically and internationally, including the world's top ten multinational corporations (MNCs). The industrial value of its technology platform has been fully validated by international top-tier partners. Simultaneously, the company is actively expanding the diversified application scenarios of its platform technology with multiple biotech companies.

Dr. Zhang Jiwei, Founder of ImmuNova, stated: "I sincerely thank new and old shareholders and partners for their trust and strong support! This 250 million yuan Series A financing is an important milestone in ImmuNova's development and a key driving force for the company's transformation and strategic leap. In the future, we will rely on our independently developed multi-species, multi-source antibody discovery technology to accelerate platform construction and pipelinepipeline development (pipeline development), support China's biomedical source innovation development, expand the global industry cooperation ecosystem, build an internationally leading antibody discovery platform, and deliver professional and efficient R&D solutions. Driven by the dual engines of capital and technology, we will achieve leapfrog growth and bring more breakthrough therapies to patients worldwide."

Fu Shan, Managing Partner of Vivo Capital, stated: "The new generation of fully human model animal platforms, combined with AI intelligent R&D capabilities, will become a powerful engine for innovative biopharmaceutical development. ImmuNova has not only fully validated its platform advantages in antibody screening for several complex targets, earning high recognition from MNCs, but also, by leveraging the rich data assets accumulated from diverse model animals, is expected to further deeply integrate AI algorithms to build an intelligent antibody discovery system, empowering the entire process of antibody sequence generation, characterization, and drug-like property prediction, substantially shortening R&D cycles and improving candidate drug success rates. Vivo Capital is optimistic about the company's differentiated MASIRT technology and the multi-species, high-quality fully human model animal platform it has built, believing this platform can greatly empower global innovative antibody drug development. We look forward to working closely with ImmuNova and its team, fully leveraging Vivo's global ecosystem resources to accelerate the internationalization of platform collaborations and support the development and implementation of its innovative pipeline."

Fu Dongping, Partner of Gaomai United Family Office, stated: "Gaomai is optimistic about ImmuNova's independently developed MASIRT® technology, which enables ultra-large fragment cross-species gene in situ replacement, breaking through traditional rabbit monoclonal antibody humanization challenges, aiming to elevate global therapeutic antibody R&D standards and support innovative breakthroughs in China's biomedical field. By supporting pioneering technology companies like ImmuNova, Gaomai helps family capital achieve high-quality succession while giving back to society."

Chen Leiwun, Managing Partner of Xicheng Jinrui, stated: "ImmuNova possesses a world-leading gene editing technology platform with efficient new drug molecule development capabilities. As the company's earliest investment institution, Xicheng Jinrui has continuously increased its investment in 2021, 2023, and 2025, and has introduced business partners to the company, witnessing its growth and progress. We hope ImmuNova will develop antibody drugs with greater clinical advantages for patients worldwide."

Dr. Ji Tianrong, Founder & General Manager of Taiyu Investment, stated: "ImmuNova is a 'pioneer' of domestic large-fragment gene in situ replacement technology. With its independently patented artificial chromosome vector, it possesses world-leading fully human antibody mice, fully human single heavy chain antibody mice, fully human common light chain antibody mice, and alpaca antibody mice, all of which have already achieved commercialization, receiving widespread market acclaim, and have signed strategic cooperation agreements with multiple MNCs and well-known domestic pharmaceutical companies. Additionally, we hope that ImmuNova's globally scarce fully human antibody rabbit platform will be commercialized soon, supporting the improvement of new drug R&D efficiency."

Hong Lei, Head of Healthcare and Managing Director at Lighthouse Capital, stated: "It is an honor to accompany ImmuNova through this financing round. From our first contact to today, we have witnessed the complete journey of the company's platform technology continuously gaining recognition from world-class pharmaceutical companies and top-tier funds. As antibody drug R&D increasingly returns to source innovation, ImmuNova's technological moat and platform capabilities appear particularly rare. We look forward to continuing to support the company, enabling this innovation platform originating from China to serve more pharmaceutical companies worldwide, contributing Chinese wisdom to the global stage."

About Vivo Capital

Vivo Capital was founded in 1996 and is a world-leading healthcare investment firm committed to strategic empowerment and resource integration through an ecosystem approach. Vivo Capital operates multi-fund investment platforms across venture capital, growth and control private equity, and public markets, managing a cumulative total of 16 USD and RMB funds with actively managed assets exceeding $7.5 billion, and has invested in over 460 enterprises globally. All funds under its management invest broadly across the healthcare sector, including biotechnology, pharmaceuticals, medical devices, and healthcare services, with a focus on the world's largest healthcare markets. Vivo Capital has a team of over 70 professionals, headquartered in Palo Alto, California, with offices in Beijing, Shanghai, Hong Kong, Taipei, and Singapore.

About Xicheng Jinrui (Chengdu JinRui)

Beijing Xicheng Jinrui Equity Investment Fund Management Co., Ltd. was established in 2018 and is a market-oriented professional investment institution with state-owned background, jointly initiated by Beijing Financial Street Capital Operation Group Co., Ltd., the China State-Owned Enterprise Structural Adjustment Fund Co., Ltd., and China National New Fund Management Co., Ltd. It focuses on high-quality enterprises in the areas of digitalization, intelligence, green economy, and healthcare.

About Taiyu Investment

Taiyu Investment was established in 2014 and is an independent venture capital institution under Tigermed. Taiyu Investment focuses on equity investments in early-stage and growth-stage healthcare sectors. Its management team possesses deep industry background, extensive industry resources, and rich investment experience. To date, it has completed investments of 2 billion yuan across more than one hundred projects, with an investment portfolio covering medical devices, biomedicine, CRO, and health foods. Through empowering its portfolio companies, Taiyu Investment creates value for the development of the healthcare industry in China and globally, contributing to public health.